

Signature

Approval for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 09/755,017 Jan 5, 2001 **Filing Date** TRANSMITTAL Walke, D. Wade **First Named Inventor FORM** 1645 Group Art Unit (to be used for all correspondence after initial filing) To Be Assigned **Examiner Name** Total Number of Pages in This Submission Attorney Docket Number LEX-0115-USA ENCLOSURES (check all that apply) After Allowance Communication **Assignment Papers** Fee Transmittal Form to Group (for an Application) Appeal Communication to Board Drawing(s) Fee Attached of Appeals and Interferences Appeal Communication to Group Licensing-related Papers Amendment / Reply (Appeal Notice, Brief, Reply Brief) Proprietary Information Petition After Final Petition to Convert to a Status Letter Affidavits/declaration(s) Provisional Application Other Enclosure(s) (please Power of Attorney, Revocation Extension of Time Request identify below): Change of Correspondence Address return postcard Terminal Disclaimer Express Abandonment Request PTO 1449 and References Information Disclosure Statemen Request for Refund Certified Copy of Priority CD, Number of CD(s)_ Document(s) References Cited in 2 Binders Remarks Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Reg. No. 41,866 Lance K. Ishimoto Lexicon Genetics Incorporated Individual name Signature July 17, 2001 Date **CERTIFICATE OF MAILING** I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: July 17, 2001 Typed or printed name Michelle Klein

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Washington, DC 20231.

July 17, 2001

Date

THE UNITED STATES PATENT AND TRADEMARK OFFICE EIVED

Annlicont/	(م	١.
Applicant(3	٠.

Walke et al.

JUL 2 3 2001

Application No.:

09/755,017

TECH CENTER 1600/2900

Filed:

January 5, 2001

Group Art Unit:

1645

Title:

Novel Human Membrane Protein and

Examiner:

To Be Assigned

Polynucleotides Encoding the Same

Attorney Docket No.: LEX-0115-USA

Assistant Commissioner for Patents

Washington, D.C. 20231

Box DD

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is submitted:

_X	(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
_	 under 37 CFR 1.97(c) together with either a: Certification under 37 CFR 1.97(e), or a \$240.00 fee under 37 CFR 1.17(p), or (After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
	under 37 CFR 1.97(d) together with a: Certification under 37 CFR 1.97(e), and a petition under 37 CFR 1.97(d)(2)(ii), and a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1). (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

X Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s)

believe(s) that be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

JUL 2 3 2001

Respectfully submitted,

TECH CENTER 1600/2900

07/17/01

Date

Lance K. Ishimoto

Reg. No. 41,866

LEXICON GENETICS INCORPORATED

4000 Research Forest Drive The Woodlands, TX 77381 (281) 863-3333